-
Repurposed Compounds NP-135 and NP-160 Reduce Fibrosis in a NASH Pre-clinical Mouse Model Mark Williams, PhD, MBA CSO, Algernon Pharmaceuticals Vancouver, Canada Email: [email protected]
Overview
Methods
Results: Experiment 1 Results: Experiment 2
Conclusions & Future Work
Acknowledgements
References
Induction of NASH1
• Male C57BL/6 mice received 200 μg streptozotocin SC 2 days post-birth (causing mild islet inflammation and islet destruction) • High-fat diet ad libitum from 4 weeks of age (57% kcal fat) (causing fatty changes to the liver, NASH and fibrosis)
Treatment • From weeks 6-9, ten groups (n = 8/group) received a NASH test compound QD PO • One group (n = 8) received vehicle control (0.5% CMC) • One group (n = 8) received telmisartan as a positive control • Individual body weight measured daily during treatment period • Survival, clinical signs and behaviour monitored
Study endpoints • Animals were sacrificed at 9 weeks • Liver weights and liver to body-weight ratio • Plasma and serum biochemistry • Histological analyses of liver sections (NAFLD score and fibrosis)
Figure 1.3 ALT levels
Figure 1.1 NAFLD activity scores
0
50
100
150
200
250 750 800
Ve
hic
le
NP
-22
2
NP
-25
1
NP
-12
0
NP
-16
0
NP
-10
1
NP
-22
1
NP
-32
1
NP
-20
4
NP
-28
7
NP
-39
1
telm
isar
tan
Pla
sma
ALT
U
/L
Ve
hic
le
NP
-22
2
NP
-25
1
NP
-12
0
NP
-16
0
NP
-10
1
NP
-22
1
NP
-32
1
NP
-20
4
NP
-28
7
NP
-39
1
telm
isar
tan
0
NA
FLD
act
ivit
y sc
ore
1
2
3
4
5
6
7 * * ***
*; p
